Carbyne Equity Partners
Carbyne Equity Partners is a private equity investment firm established in 2023 and headquartered in Hamburg, Germany. The firm focuses on investing in growing European businesses that have strong market positions, particularly within the healthcare, nutrition, and agricultural technology sectors. Carbyne Equity Partners aims to support these industries by providing capital and expertise to foster growth and innovation.
Elicit Plant is an agro-biotech company focused on enhancing the resilience of crops to water stress and developing phytosterol-based solutions. By leveraging proprietary technology, Elicit Plant aims to address the challenges posed by climate change on agriculture. The company’s products are designed to improve plant stress resistance and activate natural defenses, which has been validated through extensive field trials across three continents. These trials demonstrate that Elicit Plant's biosolutions provide farmers with consistent and significant returns on investment, positioning the company as a leader in the ecological transition within the agricultural sector.
Fotokite specializes in developing autonomous aerial systems designed to assist first responders in emergency situations. Their patented technology integrates with fire trucks and public safety vehicles, allowing firefighters to deploy the system with a single button. Once activated, the Fotokite can ascend to heights of 45 meters, delivering critical real-time information through both thermal and standard video feeds. This capability enhances situational awareness without requiring additional personnel to operate the drone, as it operates autonomously. The tethered system ensures continuous power and data transmission, allowing for extended flight times exceeding 24 hours. The aerial data can be live-streamed to other team members at the scene or back at the station, facilitating better communication and more informed decision-making. By providing immediate and detailed insights upon arrival, Fotokite enhances the ability of first responders to assess incidents and deploy resources effectively.
Private Equity Round in 2023
ITM Isotopen Technologien München AG is a privately held biotechnology and radiopharmaceutical group of companies dedicated to the development, production and global supply of targeted diagnostic and therapeutic radiopharmaceuticals and radionuclides for use in cancer treatment. Since its foundation in 2004, ITM and its subsidiaries have established GMP manufacturing and a robust global supply network of a novel, first-in-class medical radionuclides and -generator platform for a new generation of targeted cancer diagnostics and therapies. ITM’s isotope business is profitable and growing. In July 2016 the European Commission has granted Marketing Authorization for EndolucinBeta® of ITM´s subsidiary ITG Isotope Technologies Garching GmbH. EndolucinBeta® respectively no-carrier-added (n.c.a.) Lutetium (177Lu) chloride is a radiopharmaceutical precursor and is used in Targeted Radionuclide Therapy. The drug approval is an important milestone for ITM as a specialized radiopharmaceutical company. Furthermore, ITM is developing a proprietary portfolio and growing pipeline of targeted treatments in various stages of clinical development, which address a range of cancers such as neuroendocrine cancers or bone metastases. ITM’s main objectives, together with its scientific, medical and industrial collaboration partners worldwide, are to significantly improve outcomes and quality of life for cancer patients while at the same time reducing side effects and improving health economics through a new generation of Targeted Radionuclide Therapies in Precision Oncology.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.